公司資料

Edesa Biotech Inc. 股價、新聞與催化劑

股票代碼:
EDSA
交易所:
NASDAQ
產業:
Biopharma
所在地:
United States

股票表現

2.17 USD (+5.58%)

收盤價

最後更新: 2026年11月19日

—

市值

股價為何變動

截至 2026年11月19日,EDSA 上漲 5.58%,收於 $2.17。目前新聞監測窗口內未發現新的同公司新聞。

公司概覽

Host-Directed Immunology Developer

Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapies for inflammatory and immune-mediated diseases. Its pipeline is organized around medical dermatology and respiratory medicine, with programs intended to modify disease-driving immune pathways rather than treat symptoms alone.

EB06 Vitiligo Program

EB06 is a fully human monoclonal antibody that binds CXCL10 and blocks its interaction with the CXCR3A and CXCR3B receptors. Edesa is developing the candidate as a systemic therapy for moderate-to-severe nonsegmental vitiligo, where CXCL10 is implicated in immune-cell trafficking to the skin and melanocyte loss. The ongoing randomized Phase 2 study is evaluating EB06 against placebo in up to 80 adults, with change in the Facial Vitiligo Area Scoring Index at Week 28 as the primary efficacy endpoint.

Paridiprubart Respiratory Program

Paridiprubart is a human monoclonal antibody targeting toll-like receptor 4, a regulator of innate immune signaling. The candidate is being developed for acute respiratory distress syndrome and is also being evaluated in patients with concurrent acute kidney injury. Clinical analyses have associated paridiprubart plus standard care with mortality reductions in respiratory-failure populations, supporting continued regulatory and late-stage development planning.

Daniluromer Dermatology Asset

Daniluromer, formerly EB01, is a 1.0% topical cream developed for moderate-to-severe chronic allergic contact dermatitis. The asset is Phase 3-ready and gives Edesa a second dermatology program alongside the systemic EB06 vitiligo study.

Partnership and Funding Model

Edesa uses partnerships and public-sector support to advance capital-intensive programs. Kyorin Pharmaceutical holds exclusive Japanese rights to develop and commercialize paridiprubart for ARDS, while Edesa retains rights outside Japan and supplies the product. The respiratory program has also received Canadian government funding and is being evaluated in a U.S. government-funded platform study.

未來催化劑

  • Initial enrollment at U.S. sites in the Phase 2 EB06 vitiligo study in the first quarter of 2027.
  • Topline results from the Phase 2 EB06 vitiligo study in the fourth quarter of 2027.

近期新聞

新聞標題由機器翻譯,詳情為英文原文。

    相似股票

    商業成熟度、治療領域或催化劑模式相近的同業公司。